- Home
- AOMR vs CGEN Comparison
AOMR vs CGEN Comparison
Compare AOMR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | CGEN |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.7M | 220.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AOMR | CGEN |
|---|---|---|
| Price | $9.09 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $11.25 | $4.00 |
| AVG Volume (30 Days) | 86.4K | ★ 591.9K |
| Earning Date | 03-03-2026 | 03-03-2026 |
| Dividend Yield | ★ 14.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $34,705,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.06 | $164.92 |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.36 | $1.13 |
| 52 Week High | $10.88 | $2.66 |
Technical Indicators
Market Signals| Indicator | AOMR | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 63.22 |
| Support Level | $8.57 | $2.04 |
| Resistance Level | $9.27 | $2.21 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 77.08 | 68.46 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.